ReviewCurrent Alzheimer research2017
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.
Review in Current Alzheimer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computer-Aided Decision Support Systems of Alzheimer's Disease Diagnosis - A Systematic Review.Current medical imaging · 2025Pooled it
- Involving Societal Stakeholders in Dementia Risk Reduction: An Explorative Study.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- The Relationship Between Diet and the Neuropathological Hallmarks of Alzheimer's Disease in Cognitively Normal Adults: A Systematic Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Crossing Pathological Boundaries: Multi-Target Restoration of the Neurovascular Unit in Alzheimer's and Vascular Dementia-From Modern Therapeutics to Traditional Chinese Medicine.Aging and disease · 2025Review
- Review
- Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions.Ibrain · 2025Review
- Current Challenges in the Diagnosis of Progressive Neurocognitive Disorders: A Critical Review of the Literature and Recommendations for Primary and Secondary Care.Brain sciences · 2023Review
- Network organization of resting-state cerebral hemodynamics and their aliasing contributions measured by functional near-infrared spectroscopy.Journal of neural engineering · 2023Article
- Current Pharmacotherapy and Multi-Target Approaches for Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Machine learning for comprehensive prediction of high risk for Alzheimer's disease based on chromatic pupilloperimetry.Scientific reports · 2022Article
- The Beneficial Effects of Combining Anti-Aβ Antibody NP106 and Curcumin Analog TML-6 on the Treatment of Alzheimer's Disease in APP/PS1 Mice.International journal of molecular sciences · 2022Article
- Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?Neuroepidemiology · 2022Article
- Retaining Participants in Longitudinal Studies of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- Towards a Consensus on Alzheimer's Disease Comorbidity?Journal of clinical medicine · 2021Review
- Protective Effect of Biobran/MGN-3 against Sporadic Alzheimer's Disease Mouse Model: Possible Role of Oxidative Stress and Apoptotic Pathways.Oxidative medicine and cellular longevity · 2021Article
- Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms.Frontiers in neuroscience · 2021Review
- Alzheimer's Disease and Herbal Combination Therapy: A Comprehensive Review.Journal of Alzheimer's disease reports · 2020Review
- Public awareness and knowledge of factors associated with dementia in China.BMC public health · 2020Article
- Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.PLoS medicine · 2020Observational
- Genetic testing for neurodegenerative diseases: Ethical and health communication challenges.Neurobiology of disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The field of Alzheimer disease (AD) prevention has been a culmination of basic science, clinical, and translational research. In the past three years since the new 2011 AD diagnostic guidelines, large-scale collaborative efforts have embarked on new clinical trials with the hope of someday preventing AD. This review will shed light on the historical and scientific contexts in which these trials were based on, as well as discuss potential challenges these trials may face in the coming years. Primary preventive measures, such as lifestyle, multidomain, medication, and supplemental interventions, will be analyzed. Secondary prevention as represented by disease-modifying interventions, such as antiamyloid therapy and pioglitazone, will also be reviewed. Finally, hypotheses on future directions for AD prevention trials will be proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.